Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Olema Pharmaceuticals (OLMA) Amortization of Deferred Charges (2020)

Olema Pharmaceuticals (OLMA) has 1 years of Amortization of Deferred Charges data on record, last reported at $641000.0 in Q1 2020.

On a quarterly basis, Amortization of Deferred Charges changed N/A to $641000.0 in Q1 2020 year-over-year; TTM through Dec 2020 was $641000.0, a N/A change, with the full-year FY2020 number at $641000.0, changed N/A from a year prior.
Amortization of Deferred Charges reached $641000.0 in Q1 2020 per OLMA's latest filing.
Over the last five years, Amortization of Deferred Charges for OLMA hit a ceiling of $641000.0 in Q1 2020 and a floor of $641000.0 in Q1 2020.